Technical Analysis for ORTX - Orchard Therapeutics plc

Grade Last Price % Change Price Change
grade F 10.4 -2.99% -0.32
ORTX closed down 2.99 percent on Friday, November 15, 2019, on 2.28 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
0 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical ORTX trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish -2.99%
NR7 Range Contraction -2.99%
Below Lower BB Weakness -2.99%

Older signals for ORTX ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Track My Stocks
Configure default chart indicators
ORTX Chart by TradingView
Basic chart:
Profile
Orchard Therapeutics is a fully integrated commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies. Orchard’s advanced portfolio of autologous ex vivo gene therapies targets serious and life-threatening rare diseases, initially primary immune deficiencies, neurometabolic disorders and hemoglobinopathies.
Biotechnology Biopharmaceutical Health Nature Therapy Hemoglobinopathies
Is ORTX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Nov 9 Orchard Therapeutics' (ORTX) CEO on Q3 2019 Results - Earnings Call Transcript
Nov 8 FDA approves Acceleron's blood disorder drug ahead of schedule
Nov 6 Orchard Therapeutics EPS beats by $0.05, beats on revenue
Nov 6 Orchard Therapeutics Reports Third Quarter 2019 Financial Results and Achievement of Key 2019 Milestones for Neurometabolic and Primary Immune Deficiencies Franchises
Nov 6 Orchard Therapeutics to Present New Registrational Data of Investigational Gene Therapies at the 61st American Society of Hematology Annual Meeting
Oct 30 Did Changing Sentiment Drive Orchard Therapeutics's (NASDAQ:ORTX) Share Price Down By 16%?
Oct 30 Orchard Therapeutics to Webcast Conference Call of Third Quarter 2019 Financial Results
Oct 22 Orchard Therapeutics Presents Data from OTL-200 in Patients with Metachromatic Leukodystrophy Using Cryopreservation
Oct 2 Orchard Therapeutics appoints CEO Mark Rothera to the ARM 2020 board of directors
Oct 2 Orchard Therapeutics Announces Appointment of CEO Mark Rothera to The Alliance for Regenerative Medicine’s 2020 Board of Directors
See more ORTX news...
Indicators
Indicator Value
52 Week High 21.64
52 Week Low 8.65
Average Volume 183,772
200-Day Moving Average 15.1191
50-Day Moving Average 12.7312
20-Day Moving Average 11.9415
10-Day Moving Average 11.64
Average True Range 0.7728
ADX 13.75
+DI 14.6009
-DI 24.96
Chandelier Exit (Long, 3 ATRs ) 10.9316
Chandelier Exit (Short, 3 ATRs ) 12.4084
Upper Bollinger Band 13.255
Lower Bollinger Band 10.628
Percent B (%b) -0.09
BandWidth 21.998911
MACD Line -0.4158
MACD Signal Line -0.2848
MACD Histogram -0.131
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.39
Resistance 3 (R3) 11.40 11.07 11.23
Resistance 2 (R2) 11.07 10.82 11.07 11.17
Resistance 1 (R1) 10.74 10.67 10.58 10.73 11.11
Pivot Point 10.41 10.41 10.33 10.41 10.41
Support 1 (S1) 10.08 10.16 9.92 10.07 9.69
Support 2 (S2) 9.75 10.01 9.75 9.63
Support 3 (S3) 9.42 9.75 9.58
Support 4 (S4) 9.41